ࡱ> GIDEF[ 9Mbjbj =ΐΐeDWWWWW${{{P< {<"t(;;;yyy!!!!!!!#R&!WlWW"ll!WW;;!lXW;W;!l!/!{!;Ӈ{G!! "0<"O!,&&{!&W{!Py>,$eyyy!!yyy<"llll&yyyyyyyyy :  GUIDE TO MEDICAL FITNESS STANDARDS FOR APPLICANTS Applicants must be screened to identify medical conditions, which might limit their ability to complete their training or might result in excessive costs for medical care for a preexisting condition. This guide provides medical fitness standards of sufficient detail to ensure uniformity in the medical evaluation of applicants for training programs. Although the guide attempts to generally include all disease conditions, it is not possible to cover every disease or physical finding. It is the responsibility of the medical examiner to use sound medical judgment to determine fitness of those personnel whom have medical findings not covered precisely by the guide. If a disqualifying defect listed in this guide is identified but not considered disqualifying for this particular applicant, the examining physician should state the reasons why the finding is not likely to limit performance or cause undue risk during training. In addition, those conditions indicated as causes for rejection, which can be corrected by treatment or by spontaneous cure will be reconsidered following resolution and/or therapy when substantiating studies have been completed and received. The medical assessment should be based on the established classifications given in the following Guide to Medical Fitness. MEDICAL CONDITIONS LISTED UNDER EACH HEADING IN SECTION ONE THROUGH SIXTEEN ARE REASONS FOR DISQUALIFICATION UNLESS OTHERWISE STATED. CONTENTS SECTION1ABDOMEN AND GASTROINTESTINAL SYSTEMSECTION2BLOOD AND BLOOD-FORMING DISEASESSECTION3EARS AND HEARINGSECTION4ENDOCRINE AND METABOLIC DISORDERSSECTION5MUSCULO-SKELETAL SYSTEMSECTION6EYES AND VISIONSECTION7GENITO-URINARY SYSTEMSECTION8HEAD AND NECKSECTION9HEART AND VASCULAR SYSTEMSECTION10HEIGHT, WEIGHT AND BODY BUILDSECTION11LUNG AND CHEST WALLSECTION12MOUTH NOSE, PHARYNX, TRACHEA, ESOPHAGUS AND LARYNXSECTION13NEUROLOGICAL DISORDERSSECTION14PSYCHOSES, PHYCHONEUROSES, PERSONALITY DISORDERS, ALCOHOLISH, DRUG DEPENDENCE, ETC.SECTION15SKIN AND CELLULAR TISSUESSECTION16SYSTEMIC DISEASES AND MISCELLANEOUS CONDITIONS AND DEFECTS MEDICAL CONDITIONS LISTED UNDER EACH HEADING ABOVE ARE REASONS FOR DISQUALIFICATION UNLESS OTHERWISE STATED. Section 1 ABDOMEN AND GASTROINTESTINAL SYSTEM Cholecystitis (gall bladder disease) chronic with symptoms so severe as to interfere with normal activities. Cholelithiasis (gall stones), symptomatic or asymptomatic. Cirrhosis demonstrated by abnormal liver function tests with or without jaundice, or with acites or varices of the esophagus. Hepatitis, active or chronic demonstrated by liver function tests. Hernia, symptomatic inguinal, umbilical, hiatal. Intestinal tract, megacolon, diverticulitis, ulcerative colitis, Chrons disease. Rectum and anus, stricture, fissure, prolapse, hemorrhoids. Pancreas, acute or chronic disease. Spleen, diseases involving, spleenectomy within the last two years. Tumors, benign or malignant. (see section 15) Ulcer, stomach or duodenal confirmed by history or X-Ray. OTHER CONGENITAL OR ACQUIRED ABNORMALITIES AND DEFECTS WHICH REQUIRE SPECIAL MEDICAL CARE. Section 2 BLOOD AND BLOOD-FORMING TISSUE DISEASES Anemias, blood loss anemia, abnormal destruction of RBCs (hemolytic anemia) faulty RBC production including: hereditary hemolytic anemia, thalassemia, sickle cell and other clinically significant hemoglobinopathies. Hemorrhagic states, caused b coagulation defect or vascular instability. Leukopenia, chronic or recurrent. Myeloproliferative disease, polycythemia, leukemia, etc. Hypogammaglobulinemia Acquired Immune Deficiency Syndrome & ARC\ Malignancies, those conditions associated with the blood forming elements. Section 3 EARS AND HEARING Auditory canal, tumors or obstruction of the ear canal. Mastoids, chronic mastoiditis. Tympanic membrane (ear drum), perforation or severe scarring associated with a hearing level below standards and requiring hearing apparatus. OTHER DEFECTS AND DISEASES OF THE EAR REQUIRING FREQUENT AND PROLONGED TREATMENT. Hearing defect, significant hearing loss determined by audiometer. Use of a hearing aid to bring auditory acuity up to acceptable standards is permitted. Section 4 ENDOCRINE AND METABOLIC DISORDERS Adrenal gland, abnormal function of any degree. Diabetes mellitus, requiring insulin and not controlled by diet, history of acidosis. Thyroid, goiter, thyroid nodule (benign or malignant), hypo or hyperthyroidism. Gout, moderate to severe with renal complications, any gouty condition not controlled by diet or medication. Hyperlipidemia, familial. OTHER ENDOCRINE OR METABOLIC DISORDERS WHICH REQUIRE FREQUENT MONITORING AND TREATMENT. Section 5 MUSCULO-SKELETAL SYSTEM Extremities, congenital or acquired abnormality which requires frequent observation, evaluation and/or treatment including prosthetic appliances. Arthritis, chronic osteoarthritis or traumatic arthritis, rheumatoid arthritis documented by laboratory studies or by history. Osteomyelitis, any infection involving bone, including tuberculosis, which is active or recurrent, unless successfully treated two or more years previously. Spine, diseases, abnormalities, or injuries which require continual treatment or evaluation of the spine and prevent physically active participation in training. Intervertebral disc herniation or history of surgical intervention unless two or more years have passed and no symptoms exist. Fractures, any fracture of a bone which has not healed completely and therefore requires continual treatment. Section 6 EYES AND VISION EYES Lids, ptosis, growth or tumor, which interferes with vision. Conjunctiva, conjunctivitis, including trachoma interfering with normal vision. Cornea, opacification of the cornea from any cause, including corneal ulcer, herpetic ulcer. Retina, degeneration, detachment of the retina, or congenital condition that impairs vision. Lens, opacities or dislocation of the lens which interferes with vision. Glaucoma, primary or secondary that is not easily controlled by medication or where vision is significantly affected. ALL OTHER DEFECTS AND DISEASES WHICH IMPAIR VISION OR REQUIRE CONTINUED EVALUATION AND TREATMENT. VISION Distant vision, visual acuity which does not correct to at least one of the following: 20/30 in one eye and; 20/100 in the other eye. 20/20 in one eye and; 20/400 in the other eye. Section 7 GENITO-URINARY SYSTEM Kidney, absence of one kidney unless the remaining kidney has normal function, cystic or polycystic kidney, chronic infection of the urinary tract such as pyelonephritis, glomerulonephritis, or tuberculosis. Any tumor or persistent calculi (stone) which is identified and symptomatic. Ureter, bladder, urethra, any infection which does not respond to treatment or reoccurs with such frequency so as to interfere with normal function. Stones located in any portion of the urinary tract. Testicles, undescended testicle unless surgically corrected, epiditimitis, or tumors and cysts involving this organ. Prostate, enlargement to such a degree so as to cause obstruction to urine flow, chronic infection. Uterus, enlargement due to fibroids. Pregnancy, until satisfactory delivery and no residual complication. Ovaries, cysts or tumors or chronic infections involving the tubes (salpingitis). Genitalia, male or female, any abnormality, acquired or congenital, that will require treatment; this includes cystocele, rectocele, vaginal cysts, hydrocele, etc. Tumor, any tumor, benign or malignant, of the genito-urinary system. ALL OTHER CONDITIONS INVOLVING THE G-U SYSTEM THAT WILL INTERFERE WITH NORMAL FUNCTION OR REQUIRE EXTENSIVE MEDICAL CARE. Section 8 HEAD AND NECK Abnormalities, any injury or congenital changes which affect normal function. Skull, any deformity if associated with evidence of compromise of brain, spinal cord, or peripheral nerve function. Neck, congenital bronchial cleft cyst, spastic contraction of neck muscles (torticolis), cervical lymph node enlargement. ALL OTHER CONDITIONS INVOLVING THE HEAD AND NECK THAT PROHIBIT NORMAL FUNCTION OR WHICH MAY REQUIRE EXTENSIVE MEDICAL CARE. Section 9 HEART AND VASCULAR SYSTEM Congenital abnormalities, heart and major vessels unless such abnormalities have been satisfactorily corrected without prosthesis and there are no residual or complications of treatment. Valvular disease, this includes mitral valve prolapse which has persistent hemodynamic significance. Ischemic myocardial disease, occlusive coronary artery disease as manifested by any of the following: History of myocardial damage Symptoms of acute or chronic ischemia Electrocardiographic evidence of myocardial ischemia. Pericarditis, including constrictive pericarditis unless surgically corrected. Endocarditis, valve deformity with or without myocarditis. Hypertrophy (enlargement) of the heart, dilitation for any reason, including congestive failure, parasitic infection (Chagas disease), etc. Abnormal electrocardiogram, evidence of myocardial infarctions arrythmias, conduction disorder or defect including second or third degree heart block, persistent tachycardia or bradycardia. Hypertension, manifested by consistent systolic pressure readings of 160 mm Mg. or more in a 35 year old person, 140 mm Hg. or more in a person under 35 years old, or in a person whose diastolic pressure remains above 95 mm Mg. at any age. Pre-existing hypertension well controlled by drug therapy and no evidence of involvement of any organs may be exempted if verified. Acquired diseases of the circulatory system, aneurysms of major vessels, varicosities, thrombophlebitis, occlusive disease of vessels, arterio-spastic diseases, etc. Rheumatic fever, evidence of Rheumatic Fever present now or within the past two years. Coronary revescularization, any person who is a candidate for coronary bypass surgery or who has had such surgery in the past year. ANY CARDIOVASCULAR CONDITION THAT INTERFERES WITH NORMAL FUNCTION OR REQUIRES MEDICAL CARE AND MONITORING. Section 10 HEIGHT AND WEIGHT Proportion of height to weight which would limit physical activity or normal function and place the subject at increased medical risk is reason for rejection. The examining physician should include an evaluation of the subjects physical condition and review those whose weight exceeds that from the height/weight table by more than 30 percent. If no additional conditions are present that would impede training a waiver may be provided. Height and Weight Tables* MEN WOMENHeightSmallMediumLargeHeightSmallMediumLargeFeetInchesFrameFrameFrameFeetInchesFrameFrameFrame 5 2 128-134 131-141 138-150 4 10 102-111 109-121 118-13153130-136133-143140-153411103-113111-123120-13454132-138135-145142-15650104-115113-126122-13755134-140137-148144-16051106-113115-129125-14056136-142139-151146-16452108-121118-132125-14357138-145142-154149-16853111-124121-135131-14758140-143145-157152-17254114-127124-138134-15159142-151148-160155-17655117-130127-141137-155510144-154151-163158-18056120-133130-144140-159511146-157154-166161-18457123-136133-147143-16360149-160157-170164-18858126-139136-150146-16761152-164160-174168-19259129-142139-153149-17062155-168164-178172-197510132-145142-156152-17363158-172167-182176-202511135-143145-159155-17664162-176171-187181-20760138-151148-162158-179 *In shoes with one-inch heels and under clothing weighing five pounds for men and three pounds for women. Section 11 LUNGS AND CHEST WALL Tuberculous lesions, active tuberculosis or evidence of tuberculosis within the past two years. Treated and healed tuberculosis which is demonstrated as inactive by X-ray and laboratory studies is not disqualifying. The subject should not currently require anti-tuberculosis treatment. Lung, lobectomy for any reason, pneumothorax which has reoccurred within the past two years regardless of cause, abscess of the lung bullous emphysema, or bronchopleural fistula. Infectious disease, any non-tubercular chronic infection involving the lungs such as sarcoidosis, histoplasmosis, coccidiomycosis mycotic infections, chronic lung abscesses. Respiratory diseases, asthma requiring frequent medication and/or requiring hospitalization in the past five years, bronchiectasis, chronic emphysema, and extensive pulmonary fibrosis. Tumor, any tumor or growth, malignant or benign. Chest wall, any deformity causing pulmonary insufficiency. ALL OTHER CONDITIONS OF THE CHEST AND LUNGS THAT RESULT IN DIFFICULTY IN RESPIRATION AND THUS LIMIT ACTIVITY OR REQUIRE EXTENSIVE MEDICAL CARE ARE REASONS FOR REJECTION. Section 12 MOUTH, NOSE, THROAT, ESOPHAGUS, LARYNX Nose, allergies not controlled by medication, nasal polyps, perforated nasal septum associated with interference of function. Sinuses, chronic sinusitis requiring frequent medical attention. Pharynx/Larynx, disease condition which results in ulceration or obstruction, tumor or polyps, laryngeal paralysis which interferes with swallowing or speech. Esophagus, obstruction due to scarring or tumor, varicose veins associated with portal hypertension. Tongue, paralysis affecting speech, tumors. ALL OTHER CONDITIONS THAT INTERFERE WITH FUNCTION OR REQUIRE CONTINUED MEDICAL CARE. Section 13 NEUROLOGICAL DISORDERS Degenerative disorders, cerebral arterial sclerosis, ataxias, multiple sclerosis, Parkinsons disease, etc. Convulsive disorders, all forms of psychomotor or temporal lobe epilepsy except by history more then five years previous and not requiring medication for control. Migraine headaches, those headaches which respond poorly to treatment and result in incapacitation. Paralysis, incapacitation, congenital or acquired, if subject is unable to care for himself or where therapy or appliances are required. Peripheral nerve disorder, neuralgia which is chronic and of an intensity that is incapacitating, polyneuritis, neurofibromatosis. NEUROLOGICAL CONDTIONS THAT LIMIT FNCTION AND THE ABILITY TO COMPLY WITH TRAINING PROGRAMS OR REQUIRE EXTENSIVE MEDICAL CARE. Section 14 PSYCHOSES, PSYCHONEUROSES, PERSONALITY DISORDERS, DRUG DEPENDENCE, ETC. Psychoses, current behavior suggestive of a psychosis or by history unless of a brief duration and at least three years have elapsed since recovery. Psychoneuroses, neurotic symptoms or behavior which impairs occupation or interpersonal effectiveness, depressive state which is or was sufficiently severe to require hospitalization or therapy. Personality disorders, personality inadequacy which will seriously interfere with adjustment. Drug dependencies, this includes all illegal drugs and the state o alcoholism which is characterized b repeated and excessive abuse of alcohol which interfere with normal functions. Recovering alcoholics who have a period of sobriety for more than three years may be considered for training if continued participation in a form of treatment can be assured. OTHER PSYCHIATRIC CONDITIONS WHICH INTERFERE WITH EXPECTED ACTIVITIES OR THOSE WHICH MAY INVOLVE OR AFFECT OTHERS ARE REASONS FOR DISQUALIFICATION. Section 15 SKIN DISORDERS Lupus erythematosis, discoid or systemic which is not controlled or is aggravated by sunlight. Psoriasis, if extensive and requiring frequent medical attention. Pemphigus, familial and vulgaris, especially when in bullious form and requiring extensive medical care. Fungal any of the fungal infections which are chronic and unresponsive to treatment. Eczema, atopic dermatitis, if symptomatic and unresponsive to treatment. Malignancies, basal cell, squamous cell, or malignant melanoma cancers which have not been adequately treated, leukemia cutis. OTHER CHRONIC DISORDERS OF THE SKIN OF A DEGREE OR NATURE WHICH REQUIRE FREQUENT OUTPATIENT TREATMENT OR INTERFERE WITH NORMAL FUNCTION. Section 16 SYSTEMIC DISEASES AND OTHER CONDITIONS Tuberculosis, active tuberculosis in any form or location except treated or spontaneously healed lesions for more than one year under supervised treatment. Sarcoidosis, unless the manifestations of the disease are limited to hilaradenopathy and the condition has been stable for more than two years. Allergies, all forms of skin, respiratory, rhinitis allergies that require constant medical evaluation, treatment or desensitization. Parasitic infections, this includes schistosomiasis, filariasis, trypanisomiasis, amebiasis, hookworm, and other similar parasitic infections until successfully treated. Tumors, for this purpose, tumor includes all malignancies and benign lesions which interfere with normal function, require extensive medical treatment or surveillance and have the potential for increased morbidity or mortality. Malignancies, this includes lymphomas, leukemia, Hodgkins disease, etc. Venereal, any acute or chronic venereal disease such as Syphilis, Gonorrhea, Lymphogranuloma Benereum, Acquired Immune Deficiency Syndrome (AIDS), etc. The finding of a positive blood test for syphilis following the adequate WHO treatment is not in itself considered evidence of chronic venereal disease.      AID 1382 (01/2010) Page  PAGE 1 of  NUMPAGES 18 5N  =?chq1@nv Cmn6ɼɼ٭ɼٝɼɼٝٝheh^3J5CJOJQJ^JheheCJOJQJ^Jhe>*CJOJQJ^Jheh^3J>*CJOJQJ^Jheh^3JCJOJQJ^Jheh^3J5OJQJ^JaJheh^3J>56 M N $If$a$$a$<=EGEZkdx$$IflF *"6    4 la$IfZkd$$IflF *"6    4 laGXYacEZkdh$$IflF *"6    4 laZkd$$IflF *"6    4 la$IfEZkdX$$IflF *"6    4 laZkd$$IflF *"6    4 la$IfZkd$$IflF *"6    4 la$If"#+.EZkd$$IflF *"6    4 la$IfZkdH$$IflF *"6    4 la.LMUXlmuEZkd$$IflF *"6    4 laZkd8$$IflF *"6    4 la$IfuxEZkd$$IflF *"6    4 laZkd($$IflF *"6    4 la$If./7:TZkd$$IflF *"6    4 la$IfTU]`ECCZkd$$IflF *"6    4 la$IfZkd$$IflF *"6    4 la   =>?gh01mn$a$gde$a$BCUVlm $ a$gde $a$gde$a$<=\]>?   ;<QRlm$ a$$a$=E]y?M  <MR` <LTXAG "!#!$!!!!!""##$$m$s$$$$$,%5%ŶŶheheCJOJQJ^Jh^3JCJOJQJ^Jheh^3J5CJOJQJ^Jheh^3J>*CJOJQJ^Jheh^3JCJOJQJ^JHm~./0;<LMNST $a$@A_ ` #!$!:!S!T!j!!!!!!!$a$ !!""##$$l$m$$$$$+%,%%%&&s&&&&&&&&&$a$gde5%%%&E&F&&&&&&&'t'x'x((((O)_)))****!+G+b+c+++n,z,,,,,3-S--..8.....h//////0hKh^3J5CJOJQJ^JhK>*CJOJQJ^JhR`CJOJQJ^Jheh^3J5CJOJQJ^Jhe>*CJOJQJ^Jheh^3J>*CJOJQJ^Jheh^3JCJOJQJ^J7&&s't'''k(l(w(x(((N)O)))*8*^***** +!+++m, & F$a$m,n,--....g/h/////////001111122 $$Ifa$$a$gdKgdK000O111122"2V2W2222233J3K3333333.4/4g4h4444455M5N5555555u6677a8s89$99heh^3J>*CJOJQJ^JhKh^3J5CJOJQJ^JhehKCJOJQJ^JhKCJOJQJ^Jheh^3JCJOJQJ^J%heh^3JB*CJOJQJ^JphhKhyCJOJQJ^JhKh^3JCJOJQJ^J42222 2!2"28kd$$Iflֈi#-(~ Nbbb04 la $$Ifa$"2)2/262<2C2I2P2V2 $$Ifa$V2W2kdj$$Iflִ Wi#-(~bbNbbb0    4 laW2\2c2i2o2u2z22222222222222222222222Ff $$Ifa$2222222222223 333333&3.30323:3B3J3K3Ff@FfFf $$Ifa$K3M3O3W3_3g3i3k3s3{3333333333333333333FfFfx $$Ifa$3333333334 44444&4.4/41434;4C4K4M4O4W4_4g4Ff !Ff $$Ifa$g4h4j4m4u4}4444444444444444444444Ff*Ff' $$Ifa$FfX$444445 55555!5)5153555=5E5M5N5P5R5Z5b5j5l5o5w5Ff81Ff. $$Ifa$w555555555555555555555555555Ff:Ff7Ffp4 $$Ifa$55g6h6t6u666677`8a89999997:8::::::;;;$a$99999:8:c:d:::::;;;;;;;y<<<< =4=5=a=o===== >>>>??? @5@6@]@^@s@t@@@@@@ࡋ*hKhK5>*CJOJQJ^JmH sH *hKh^3J5>*CJOJQJ^JmH sH hKh^3J5CJOJQJ^JhK>*CJOJQJ^JhKCJOJQJ^Jheh^3JCJOJQJ^Jheh^3J>*CJOJQJ^J3;;;;x<y<<< = =a=b=n=o======>>>>?? @ @@@$a$@@@@@@wAxA;B*CJOJQJ^Jheh^3JCJOJQJ^Jheh^3J>*CJOJQJ^J$hKh^3JCJOJQJ^JmH sH ;EFFaFbFFF3GkGlGxGyGGGG>H?HHHVIWIJJJJ/K0KbLcL$a$cLdLeLgLhLjLkLmLnLpLqLsLtL4M5M6M7M8M9MqLrLtLLMMMMMM M$M%M/M0M2M3M4M7M8M9M߾heh^3JCJOJQJ^Jh!)%h H0JCJOJQJ^JmHnHu heh50JCJOJQJ^J)jheh50JCJOJQJU^Jh5CJOJQJ^Jheh5CJOJQJ^Jh5jh5UmHnHu,1/ =!"#$% 5 01:pe/ =!"#$% nb- ]5O4޿DPNG  IHDRI8gAMAܲ pHYs\A\AF> IDATx?liz E^<L,i(m瑅3`5Hgp#c% PA џl!RJ٣F5f8 8A)^/# ꏿr8/T>?~T(++UEQ遢(w+l"vxz" Z4)_*XqO= GtKy=p@5<+൫AKb_EhG=Ϗ^M?TP 8b6g̻˗'AjPSFqDi8*esVobP9Uߕt>dsV^p o~jަp`g7V6WlKP|ڊ '옙xPJJhKSTpY葂U23&~q zkXM9ETc1E8DhH`]$6LO$"qft?Nll|^Fa2t?7v[ Dp V.fs8Zۉ_ IT(rj;cPQn~]ZQJ\֔YLO}3udl2H8EojBτI3I#!Q4^lq iZ4Խ3DwWŤAկݼP_WpN-cpaSCѐAAf~&>$y=PG0S4^ꎢ(_z=Z^lɻn/R}~dk*=|J)!ԃ2 Mٜu+OF݋oDtɨfW\m#i0:_%p #ͯUkpPTk5§XLjz,]H?3n {q. {VRO-y=H}^&Qgu(DQ&""Lesg[oR/<5Yjfd6ǗͩMs1em= FmfTkWWk(2!['GQge =|&a绝6,M EM'҇O)2O'Tzи! ) ߟ#aZ"Tnl3 YC4Y͵Ƨ|^٦?4H8`?++ƥ˞>'r*Ru;f6=P_b|<#L^ wxMWwC/iZ h(VABH&6YmzjOFUZ^Kii.Ӕ֢!Q@ED0ztru۹2Ql[_Uq:Ip Vۭג`T6_Jۅf&ofA?9|zp^BJuk^쏞AN}<|n'G5EQQcat* GǍhHԵ\`ZA-by=vQs  D~RC}l+-m(J*M-HLjqsKJ*%WLjDNRoFZgHly=es[ShȮ7(> Xڍ iRm9Julfe?>f<׫h DSF5q}S]DÃ&81y=APpC75DUrEEi"ݗErZHQH8lhzۥn'}SQEQD'ÓZG HyqQж2 Ow?ӑiԔ^]KӗY$`4g6g5EQ>Xf˦7;>`f릴x ͸>P`46ܺ(l*g*=Y.Qitu6FR*~E?HXJJg+R\qyl P_sZ4ECpG@^WƼs*ECArdP6W,RM[vK\Q~CgW4|MV@YveʕU;z[~H>qks#'qqh?>5]czH^gעQ5AgzYrhԮ0ӮU}**%&M߆ ͥ_;wX1zR-}^zB~ߝ\>ݾKEWɵnGUy*67kiqOu+uf&oW:tPߕ&Yv*-m ʕꃉ8{U#ȠO{CrIwS /mbJMTtPRZ(T D?1>|&;>bOUFчʶ;Ӣ6=7c\^\J+Ow|w]Ʈ#Ie$KM8gJVlamn?** [z WT=Zl,Mic01~ϡ{3*FX6W!ڬk_-j Oo.߿J%kƻ'V#awEڧuլJ .7L>nOHmndq:fٜjKuHXm|rZJuuve2}^^j\֍fzxvF6g+zFPO됍}vG-.\WN7+ҙ$=?7UT;[no |>F{P$K8(W)#眲es|1tɟ]s#E^] VV.n*Kuh>Zs]2^Z4T8:n9!=yrz2cQ4XT44@ætcӃlx+G(C0]PcNXJX\>6vR]p ">gqeNKu'G@c%1Lc-f7%ƇKG> +ÂF>{ƙ|^HTPNU )`;P"44zq]V~a؋ Y>c9; ](^+"-'Ѓ6**XMhթѱBs;<ϣgFyFh,w~'u)&g@(p FBr29\a\ Fԩ5=vx Ɨ K{ڥF85,>~^ˆ7wcV3K;8 GYCjYKNQ/ˁ~aaEojqP\oI8nTum\AC'?oYU%<(>,<·+ONd=&v5&J` !DfZF^igϟrfLCCbjfZX+-͍zEigTT``.=8o3񓅅>A|kstW_|T=֗/۷7\^)d*FŚ/P4WbAþA聑GK]hrGZ] 3&HxxinLgO?+FɤO',;y?u Ym~),؟vXά<⛦'J]o4mFgV=^1qx"P_%ͽѾy%DQPX/orgA'owkZ֮OaY=>`Լ[ѫw/Oƺٳ\#ICFG'Q[=Jf~v4Xm5|P\߫45_s9d9lG,-Yx*jG(+|G 7._/ fp 4mVևqſZrQ ?UkMݨ5=AbY*kvNjy{uz ݱdz\^Z1]ĦCf VV4=qr&˳z.Lb mz;{3=#=XUjρ8]<3.L FOq#!Cae{'k-ѢQjirR,+52gg'8v\DwXLجR;|kPvM^{F;֬:Ix4Xp$>XjT$s-9%&N Ú#ucӎ1}HYBE} ɩIy;ARMHJv_JNow1\lK7uG( '|gxīF 5~SC&0vj*j(ϖafkU>t.O &rM.|~wM\x2}'OB3fTTWg'?t.sMM09%Ir9qUU&%|-GXFCc8LtXC8MP17,*w9ߛ#!ݴRY-S g$)ގD]OhQVOI`uǂ0nBFir朴Y-Ksch9 0sۚȪJ}tf݄GxԒOIO̊~ݱa ao˵(&8d ѾSsbY1n}br$5ɱ2vΝTx+._Q&PxC Y-mj>KFY/ܱ۹%P#߽2k\3aGz  Fֳߡh93\,06b+UNM^HU埬dfHCЀZ#=q /wO*lst.[5zŲB~ᬙ#& 3Nx˵c ~G`#b$XR g ?$Nm40;GM$פao\DwXȼ&j._^$//xL 5rY-6!yN7kb?85^NH8kx:&#޵9$-Lb˵hgPOo["\^$ F^j)llrg'jB7v"z  (*XUk1C8l:JCIVKSenrsNFg]h}a'KJ=~󞦩&\$mG,KWX1nUKNwTfK"Dz:#wF%GqD]άTV; IDATYUCbǣ kק&If%CG§߾0}iٺomxTN⬷VLmVKl:S>&巂KW^y9AF;˷65Mn4[CXpEnOVgF~8bv-#w,y{IHWsyNt ^8J4t.Yߞ=TskP/=?G`Z&>^#QY>ԞuO~D 62med~C1U_XK MJ4T3+rWѿM#᥹1+ZZlO`t:0.gdCci\ӏxR1JX4 .)I]a=~j %vAى@okYU&{i5dS2M}NZ[}6h"IEmVܘH*WsyVrr*kPd=rגSk%I ݱ,dD0F40Dp N{X̫?Q,ע;78ݒ X#I"QuJFj|573:I_8^&NDgR~?KURPjrF߸'W%rUڬS"7Q^ kŮHt.\,.VF]{b$daQ*{YU {rZCʅJ0>uB2ҙWnQ,FgV4F F{ld ǙZ|֍fkr69 K+ vI1Ū}.$e-~7c <^^JԫOpT=uF> FY)ZrcCIJQ~# Lה"8qrk߳xcviZHODq*NHG#_%&62mb3=fH]_ܓx'8@ u~<*&RT9 ɰ5vl`6"3r4>dZ>l^ZaO Y7B7ڵJmV巂`{CX~ZoNtfQ~4.bxĻjB:˅鎢fD~wZB1Ms/U(ά^73[rF?SQ3h7iEUάtJ&bTbE3$䔹ЈDR͙Z7qjwy "b$YSa*r#/vSspr$Y>^Ya$Gq (D=8nb.Sǖc}UKRQ;r-QM}q)mF +ݧS).EbYi'rcC8=$*V02xԯe6sK.jvC82Q~1hSQԐcW '*DmVKl:.-N+[þte,<5R/k>S-ԤWfǩǣ 7SQ 0{E|'35gI#vWc6] l]Ȭje+E/XCK\'5z' } =z_}jL> ӹʷ}yN<~R7Wf;b {of rFR,+~fz6<=|rigcI}5ys|W x{D:8ϱMK8|/znznЂt.wK޾4x Y5ebϋ?SK"w{ VʻHS !αGSGe=$ラ w A\o=֣ ƫ/<_z9Iegʫ/A6}/~?߾zhQ})8.I<%B8jn S[Cq fJj:r98NG˶#U5_=}7aCbWfz<εS|#(o}GzP =/𡃧O[m}jzhpzʅJ0l".gh"8ל˵cW۷фXM+uӶvr0ɯY-[5kYH1w"ҁ:w1m]y"mhB)l0#Q*85UX)cƑFY)_ ,O0ЩPPFF*U:ڎWpXkJH'q{^~?Ib~P) =E$嫗] BPqk9ӵP5:9gPW(r, άs^>Wk^t2.PzT?Q=Ʒ `^2r/247_noJh`4˷`*Zt&Ŗg.BbSֱA'&S{CP8Aؠ9܇Y\5ٺྨ^`-6XBّ` PϷqX|# T@H8w% VP!!%* OW(z63:(Vr3?䕞vrQVcYr<`7CG 'ME]m-^xr뱣ͯw<:,>=mNʩDU粧3զѥPγF{,jV*Wre9]JU|2;[qQ*N|m*Op>swxr+n#݈*:jǡcG^H8?[ߟЎeR{ ow#lݨ`> o9ӵ9 'B_;^{ق:݈Ώ*j/_t ޿ my =*ޞ98˓} VuQE WlŪ,=SV}@]cteUy<*:R_6(Q(L־?< M$$5ށS'P^3}?KG:ˬM(+yh0bŞrҮ|M>rfB96h|N12ww_5ށJR=8ګݣ-ګ5`{t#:OV!Ph|WihnZhJ(6$?+q^>L%d6KQݱ@}h$p]tmգ(4?L.o夢)dpȱ5FP8A9݁*jᇟ#݈d?&G~zϐV_2^ s0jEo_gro7xH\Hw 6KĐcQ[(N cgqr^aEn )O__7Y&w:RQL.OzIu j?W{ xk<];?U;wzmV/Ÿ==5a&#a`wgb1P[y\i/ P͂@Ŷ ;[# _`5_\Š}FVJXdCY>ƻvM|JEۮU~I:݈tSPMFaㅰBY0juYzga̒16^L$?hZt< B=Te ^5iیJHE9{%e39{wE /iz1e|w;]eٍHv#"suœN{ x2S0 lN__/~ٺ|Qˬbm3Nd&$;42(=Ei M`}? =HAƝ$8l9 }er pDhőHHAv_oun=H}9nOHj/J& MQ*6Q1MMXg,= 2ꥏ Or]7.rM;sȱ89:WEڞ둾]{AwW|Y6"U_27}}̲1+@-+Y;^ZAYz){_cFx Xd?NbJF=]N'/EX,+ (xr4h7_DoU:֥Yt f oOcՐcUBF{IrQW~ #z7ͣ`4Er.HrQLLҦ=粿vVCX묊Qs-NHf &z[h\iziV( U=izFHF3|SI M3Jx)\O9M%B$Odh* z.ޅLnJ76=jSv[iRqRR2JB꙾B@djMKNAvt^s^ /q?_КFD`ꥒnF}!b7ETU49' 6a{~P >% tZ{?PTQiЎB):Bc?E0 knD^Kh7ϐNYM) O'#d,L9ܴ/٠ozlZE7 LE&;5vNMXyoʞ C4 E]2W@ft;vXv#Je7"#:G5ҭEp7ޕ'޽Qb7BԂ{pH9W 噼 F`q\-ކd 26h5uͭ!@uՋakݎ]A(NQ-\~I#嫬֢dzTU#ULd2A_`d,nk9^ϡa7] |RR>b0[ WU]<ŧok1#Y]6M#e_匪/~):S lm(Ɔ/WVBo5kG}LKiF˙=vI>H%ģF܍`44[bsgAMV9N@@SQ6jXJn1<)퉕^tQrJ@.K/d^@H/ 5S[(]EG@=4<4*nD^@{t7qnKG5҇J3ĩ zL_`dN& uJ(RA* PY`#M8o{R{‡-2:Đcqdip9Yz-K2=jǿ߬ԫhJo)lKAҮGhr;L]s3]Y '߶{j cK/OχOP{!t^\g.bK'g؂`@djo= 3r,OEըM>E4ᾊ3ǕsŪ + 9>)ed3*Kz/G^@;3_cߋ9tˑQYtE H&J 3dV~&ԗpy2on?ƷZE[ՐJ) hujZ"˟DMD5buC2}F6J?:_x$ nmoq@`P ҟTF}Me* ,f 9 _TtrOf']66hF* }6K;9.BjNZFRZ"C+Š~ucJ^ >Q{ ;?.kq:6C cp^>''r0gjBY7PۏƷe_vPȑv+XtMFcfFj(`WQf%S{Jdv%C !-DML.U46hfThfryvTуГ2 15axbT ~l_g.9/3ww _H G~s#$|%-l IDAT2k @U`R9K+(7綾49=Fys M>KfV;mk9?DAl`s3{gb<>Z,HzmQp+\J,8D -4Ih$/7j‹.Bm Iv[7.UȤʮ^pWu1ۘ ]݇f>3xu sm?OPLMAPᣗ#X;RIDٽ# K4ciG; fF&;`xz/^F?pf-tES/6Z aY__n@;l3U?Nb >kP1Un5 kxOX\G rӨtZJgHO=M12 &y٥A ?/j~^ln(6@.&hPCtZ/-o {γw/ ""UԷw5%Fٜ{zprMLvqkwsb'S->:}SZEU"mNe6s|}ݭ*Fh\}vN˶jtEc8=9#2CAp2mg70LhО?9KSaیKpy; zzРk6k)&km'&SĄ"VۭFNxWC10JE&g鼍(͹kW [ qc>(zX(j"Dq"%>1]B0\ vIt]{=o~P͓G'SJ$##DKX67irCKLt*eIR4>IE f<_毊TwHLQ69]?zEeTX I>y˽y>ͳ9(حs+~ׇw4E`i:zٞ Z3@xr I1^,[ZL :^*a،KKbSTʂ:zj[SMcÊJTԌ"mX\?y;\T;;|ž{s+~9P+>O@h1'Shb?3KR<=Sw7k=Ȭm=~? [ b"?R`hOP n :Jģ+0 @QlMDZy&??x֮sr!cuB%F/-Ȟ9:h]|~LIgsW2{s uc[ˏS?D~B$iVO6bMY0jh1Γ6>anaNU1J %Efۓ P3wyv%Q= I)by%xҌ <MP/l߄++^}m}k$p[ԋ,k%l3+~yb1ÁWBRTZEMj.k)?޹_&F"n5 εP /)+(2nrAPw) pf-,(݇o '@Gf-,h¨XvQѡ/.il"Z A0ww;E PH=f PVy(-z(楜iûw5 :X;/N;߱y=(ߥC4 @ue9<#FپA#ҡX7:c"9wq;yG:yURiEWlR;Ɇl3 [R8_ΰ7M9 CF\Pop`֌BѱK'?= l/*@} R gvGin5JQpȰz٭r+[ .o^Ds~5R› :B'`(jd|x(e)h9$66N7yѾiҏ7cvhe>O7'$s[OkthCsME5h̓(r:E3#-SCrGW>~(]M{Z߿Qnm^|rǩTeWb%NvXJǓ)ZX-&IVAvsPفl+)^Tn5"Db{GNtDan) q5<0ŔX :-oDѱK }L=2m=ޞ_TtCT뗝AXͬ3k#-RzFwQ<ٹ9JqDD Th<|S4 tN(~x25:9hES,GYޑhU WŤg0D?,]T6{dtGDR PtR.h>qT9!,P=_v{᥏*?HEh< .onhad\CV'H+Go,"YrUJMp~ 5GذOJ %$"U?73WBZP`MTH{pK(H8&ИTUK74_@*} wU$*9 #mEp9WKtsuE]g*b*wxlfyg/։60g;ќښo+Z?rKlN10c`e]ɸ"fDMJhЦT Fq΍^4ZRb CrQKIښ*َxtʰjA(욛V6GTf77Jj'ST&;u?(DD;-=ݮi} z?Tb#n~Y{>zAeSC(J. e\K(}(q-K$N"UG hNeSV:/%%c.g[uͶ񑾵`~xU 5Uo>*OB~G%mLG}74X2d@H ve+zg[znPZ`8&>$p?Q$/]ǿ?rwߙr[鉫+{ Xst=#҅hf?bIU ǔ,ZmM\}+2_?T9:*Ic /*AԾ][S57qY>%uץ8d S[S8n?ݦ˗dzـ!M >Ebh|  W}2|soO&ƮrE LZ}> whǢBijeSLFqqJzxtӴX.=zU #xQzUKrad,;|ZY11Heh}̦$ T&10YTGH;:F J$ȊUlw]?|M}gX~~{^,pG#l})MzPp*p? |sQW>ŋ%PI.,}v RNho/תl'Eo :V}Ո9pl=w  }nhg`8Bm 4 dL_?%!#ٵKew@IW3n=&|O +؍d1oU.PdË@zҡ6t gEo6p 6|/UZQ"9"RF_XTzt#=ձOKWg3Ǥ6_6Zgz){{kT^PY]ήb3\,еy\ή=|{V}#}3dǘ7+XQ>oC&|k*^\8s [ĴQ}V_0ˣ"=jX6i&a;eS]kQO9'RTk6ۥ\Ȯb=X$DVTZF#Ջ޹˹Bh;JE#P|ĺ]zEr|S?ro,ꃰ(ؾ`uуM\nBh7|¬Skd3d/]\4 #,:&Q1Xi&P]!%*}I6Oؖ8z8Ąȍ18_ԧ zC ю@^ܴX隺;E'FlK4I A S-=ñ܄?w#}P)- Je1Fb;r3>[J(%*=kkG{րy 'K,p(2rc K{_ȘF7/;izu㞋Nz-KLT IDAT1ݵrQՄ@\_Hv Lvݶ$LmxgUljʽ`nWvP%dGMƧ;&[z<M EKKmuo |3ܫU5'>߇G3?ƽ%k*_{>wBPVP&bE/ 6k_iwmﬢ?5Uo ( (-V$r-3[Oumomڤ2H4$uK&bYLy+?I/ch?$}elMP$CFqQI(#фO_[,skPH(Ǽ9¡V1 @̷| =$ڥ**ՇϝzѷΔ|*?_2`Ql%lqH4.~jom4V77q3 HGv9<}JLۙQ.eݿCwya6}^zA"Ѹ8h\ym2fX]>HgO dY*4g~Se]vD @jdyg?}q'4ڥ#^/kopM.,5]5YU䃀#?_QNrQñ'#xqґ:ٝ9DdE5/ HSQ4JWcwCH,wڥCmb)j[Ot{I.,}v 4_юB3ϗ>Wg=r#= %{Qw5կ%zcR 5]f;E&F蕏4$`7@|2v| 8}?{52`UM +,妲zv)^ib>H4 rkkP. s9ă7,_iܻ_Ҋ̪F cG`;HMH.v7hGKcoA3EuQ1*~r=Q.Z.{ ,`rt H4ku6am$/:6vȵK|뉎ʦM/"뉎Cm&9UR~kJQb>T&K=h!nY<SH]-={,qvIfU K\Or{ EQ艬14m-5UD}Wi#HX`7=h#67'?m[Sڥ ڬNtN^{wNp@9|$G]1cFV|RK$:(`7Lnz[mMU9Wȿ~~ ݜ4zoOZI-ਛ~'ϔO1^ᘸVQV@W{k@?)}/,RԽՎɎIؗ]Ұͭin(7ZSYr;ÉQ@@k33hbf©ΣCЅ5u?{۷#qܞˇ2`8$냎!<(x%f[ݕ.U,5.xWgI>h/I?+(4Lb4W$SYn/Q3 Ĩ:ą!1 r966er{kAk(]_ԥ9ғ Ns;fVs};Jޑ{-JO uZ[;mu̶@jomn$RۿAP 4s-rx_d#^mX(+WI*1*4Q<(u\8u}!~kښ*"DTqHMwZz<39'C(~+xJO., ʄ&wKRQnJk*1S,`h%ׄOk[y9(ԫV뚻0k~/*?_JMN0XS[S%N82YfO>]~E`_0˵؋GN/}uEs'e縕D7=Z} Km[,qFQrQ@\7SnF{@N;d@b1010R%>-J_}Fw7 |/Q{i-%9:n$v D f^|'7 ˴C(#M7'?R},YM tN[/i ٭&Fy)%2 D)FiE"QЃӎIKeSV *OSYa{]Od/X`VzDΣD5^XQv'a]`(-pLXam_(]v c>H?(.T65:90UT1{?}^muh8:8yh#=o9 "]2l-ҡ6;ELɅw~./Dkuhnz~r T&]n >ýq&(zztmtF 8SK7=qǘQI3z&;f$.?𹓼ww&2Qw&rғ?+4u:`8iC+/b00f sFQ+ݮn4ң\Ԩ9jw Kaؘlښ*6OU#ѸiGpnz#MN ǐ5 .Qil?ru?T[cƨEh@bt#-N8X,\8At3M1`F43(QveseSߓv7 XO+QҗKN N&1ftnEbS0j&GOr+oh--/ SE.|u6~Fq'jkŘMh\G3:f gLv,&% 潎)tMv%]i-21J9\I?>0`^Yz(ɢQW2wT\Ƕ6GbV[Sh ewv x/|"7P4 ߚbTZ(QM hy?1v΢J9&2Y4Q[oHIeCIm/ý 7PB@TAYLjR)T'xrT)}`8Sg`)U1fǡ]XľH410ysSt֫\XBI*C鰞XV24Hm^bt+jWG?TZ%o.>cv=r13 s9hG0G|xO_:G;b}b4ޡ@"Eo)eJLֿw f<)s~p~P]}b4M\Fn ¯uìV (붞(m/uM' >7w6{jAԂvmd"ė$(>h":(Ttˊ+2I ! ;psqz>)dH!C)Y$牔('F`/ohon=}AVxQwT``;cXIM_4e H띿$ ~^Ge i qLW[VzAYs#QD}Ρ֑#νv u0 1uͰuTm¨gFc<;[fI7vb7_' =!!~>^>y/QHuc%SnϽ6OgJ/*?J .]8rը*? AM n=hxhx8'{1Ho i)Ϟik cF? S!O 2>EA [$`~ȩWîYn"F.ۄQ 0b:?b:۶{r E$x`ƌB^|^imz_ݺdڍ[®AKqN`]j]uG7&Q E*m[$4aaB8m8arr}/Aj7쩩7Ǎ;,6<1V?3O!HQfNFU`PlF@'^$*֣k7~ð Ai#Fm]5GBRHS?Zԧ+ףy8B8S8e-b4y۶m۶,ZGygAe !A0Ieh+q#‰kuvp( O~yfϒB$6LWgi~t^IXiJ{+UQt**˄硃q0MӴmǡ{γ R'''A)4f/_:2yb1UF)̉CuFK/W>-] FA =s؅W&3w3Fi!~RݕjfLQ8^y7Z&O8:F0$IJ$irf !` /zOaDQro)\.ɀr_,0 Y&yqc-+f*}R‰G6{NA3wE}?~",JU+*J9. fٺUںU Avc4FpFtcF2]‰kc‰1BIHwvSi):!7?"#^ _9j\go~v@i vh;]qEah\Ȏ-e(0[IeAvڏ(U0 ),Wm|'4 0 eYEQj R P}-C)‰1Q8g6("ru4ڨ/ԑDYFzbTTQBHG GNk7οwph؅ ğAw2]UsZZZ~afLw];\B'DeYfTZ3 0& s=W6 ˲(RD;%Iey Sfo<Өno<Ϟw?Ϟ@OJ HT_.]CEIA,vQBȱso]B{3ǟ] HFNh בޓs#g[GXEK,~fY1oY${j Bm(t8D[(qMӆ&&&4MRܗ~^N5|OAdȼ(ZmN<|,K=7~vMqht8ZC1C߼v#Āx=

3A^u,ˎZ,LfRT.dYIF*2HQ?̬:HQƙ(ND}T(HNҳǚ2cۼI܄7Yd# q,˚qV, 9SܚtbM{cZHʲ,((BKӴD"qT*iHR1 6ʼĎQA"pWj~,ʣz 8KUS*S:O+T&gb2mw|Qkf"=0F TU!˲@%̔ -T4B`τeID'8R >irSUթ)z`|GögϞ/HXeu]~YAyޏ6ZضMAZ0 ֏yw7o,Uk #1D+ꕛ&$t1KG^~%4H'^$*e󳛽g" Ht?%ֻ/5Y{Hø!x]'TT$q9"ò,۶ܹcY,ӷ4M;wǶm&u]wF5M[__vuIt]y~}}]4E18p0 iʲlYV./뺪t4SSST5Mӿlc骪\ZhT۶u]&VBITm7iٶ ڶƎ_[O6m_az3UoV=ϫAʣ@Y(\~?B#cb=G`ViV)(aVga3r? ÀĖf<7FՆJ]5U#>5YqRTP`YV4UU"!D$۶2!$ϓ(߲l6( XA+Ǚ7 ˲L$Q۶Ad2e|>⦮ЛJH( ,x4M )OkZO-\aaً_Qmy* yV{ӑ IDAT Bѓ0A}ʣJ,j,?]* {3(!d("J_[9$8>ͦiaPEEQXMR itARM1x%5*S;o ia@ϻeJ%۶mL&EQ˭&۶ NR*2R]$0E P4Mg[piFÕ$2+]Pj6d2*c"? T?ge/]_GC} .;F%4E+F=ú8v!#Q?/ ˮ"gwvڲ",<0˲\Nq :QMMM;%q; w²,w)8i }d\q讲٬i $L&&YBH2&˲4ͨOpe2L&óe5Xip(`y%B+0 B@|g&ɀIQU4M-TXeFXxrǏyf8Xo)J$\P>Kü>lo [01~4,+_Z.6>װKh޷"/OBzϜOn= ؼvc{ݵO '|>" -(3eJ%*9bTJw) TXyn)P-aZ6r9lv\J%$eYD9½ ƹ9]ݺp<)"褴NXH&d2)L(^ b% Àfv aq\.s$8_!D442}Ѷm4+\J?6D`kސs# 9ALWgD݄:b,]Q;"_)LO~uvMBF"עt}?a؅ ^<8F֚F[mkf},tնmEQܲUqxwTaPS'z:@eUUA`uPQɤ,T0L"G˲Lt4;0`L,:.%Ie r6yHt ‰g b;v"*:,d֍H`NȐ RzAn. rhB %up 8Ȓ^8:trXg]FlCd8}oPh$ 7>hFoȏH1cc|$ ![o[v ʁO<ڋuF !|QA&g_?ZB1vэpƇGi pGdYj@kQ<W뺄oBȔY$I|Ϝ+$siQn­)A De.ow;?y |eVޯ{#NheW1Nb%wPEdzܻq[m h+fD` 7GAK@~xJuWƘmۚ|k$p$1F)-pwFx|*;U)< S`=h "G>KG@!z&`ַ= ȇ37'JMMW.a|y/] H+U 2MPJ)tOw:(@eYUU P0ͻݮ(QJ C븦3A=F6TUXum.qhcaEE\/xLTݵ :DяNiԚ'D|Z<]"8}/,1 H]Xd{dƟ G[V%[Q?] G u!-u~2"z&=ξ-ced .͝9Tvbt"R}Sv A/J_F48FKX ze"G!0 pGQMi6, 1o6UU-UUU& Aːe9, I ɾBhi]W;xl~I~pRe{Ёϔ]@|G_ZV?=ԠA|iBs=to\ ?$ LYض TBHǍFcGԶmBH^$)o\EĠ`c̾* ԯ1Z"W>Yv HQ|oj eS{;w?)Q`Ҟbr%SVm Hܯ.allQa `#29cV+;0 XFW&chPJ%I Hh4& >n,u1"U ;&W+~_U7ypnS|t/6=Vv95V\v "@こ0h+|F_ `LFy m55J_=29dYKC^eYVEQmڴ1XG N廈㘷%X {rh2 j7ST zwU@iƫB$W?şA. G#i48FGVFQvD2۶ j$IO5sRE{,j BHҺߞ2W.a{Ъ94ֈ1ލk+'#RY0/]SV:IU 6u^pu]H5M3xu]uaSeaZ-$u=MS(`MH}ߝf$?|oxBH./QX^Gf1ܔ3"bm@_e06?Wۮ0;Pb%8c %:Ŵ1т<a'TJփHDZiyU"I^:CE"U%Rഫ?V!t[Snz.Bk/]X8 Aj"L=-ctOA5F s2Ɩ),wX>]u]BiqlYY9yB)/f,GT: vІ7QI>[v R\`7#)kᅲ{{gKeW쀵w>A~qp::ʲ D$@{eRm?J(R.W62OhA`Y,ة V5$W?~)ws#Ȥ)$3ݹ[͛]C"bmT/Z*#T] d0 h4|z$떥aH)qqE=k4`bתnRJa*:uj{D"L)! `a) FkU׿^[9WvH={1l("i$I׃)-I82)*$quh T$t:%IH$u~[e$I< j #sWGҳ챈YG,5$RGAq~qͧ"|FO(2A,%lv1i4(Y 0 M@j(1۶5Mk4B5Md| aȿ!!RneY^ڱx|P_H(vvO16E~,ˣo+IͧDDȽVę H4v2wF'OdFyXEQɲ fILa:c~8VUU$IlN4MAI1MtSJUUC#좳|y7JqG$jt j/fw1h.Κ][qhE`Z ]]:FG~0bY$2۶`0p۶WWW7 NF1QIvs0䝪灍TQBȐ^u(!@8v]hsȲ̥U^$Ip,,hJM$8җ| bdV11Ժ#P=Ǐ;/).!a`*77^K'::b(]+5zZcv...)͒.4:'ʲ>˄1XG})kc rٔRiAR !Ym:v *ġK@ƌe.Pv!S.!M<EOf¨ 5бʲ햮FQtFd9sԩ [mv(Eu!ut-*觺GQDZ8H JQuUU"2!q]oiܐ[Y0pd1ݹKKeW!>˫]x@ǨH?/YV*f갶ˮA"]rF_gru Ȧݑ0 aF|t뺌^7|;48٬_~#eɲs7J ")0rfy|j^~2  VO>\5X/͎Yxc./om$-?cqwbLU R?ijۿc J)LuTM?}hDždR=q^TQ۶ !oumUQ@un[(<VEQ}WU5c0@$Ѝ[jc +$" A*V}I&ˢxr=lCv~DͲKhE9v@dgKe0f|fGQEN'):v7 t0 4fey,s0Ipnз%Iqtx"_ C ygf$A(?$O'cR O#MDӴBn(Yz=v5{+TZ&V\v n~)LXȶtt*&EU%8v ׿^[9Wv !xvQd 0Ơ?S,+, N$IhMaڶ m||e3X HoO)WZ٤:ƙhU,{y#Aqz;B$H]u.JH#?*o4\XOGxAL7T%("RV &H9@8<ϳmiy4 6~mB*j^jiF) q: *;Mz( .h4(`/'4MB뺠ϡIlR7e{UA$o HK4:v'Q-g ]B*;BBdr|m=!K%5FUpe4Mr6 $ O tqqsaj@E///Y휼dB(c,_@\vg.\+Wxx:\tI0i&B[!I`0ENin1R[z$g?ñ,K$I4!=<Ћ-;'`>$)R0 2C$—J%a%:#~ײNpy$pG-9 `-\LZCŢ(* eYmfBzA`v pGh9X.28oVQM(ʃC'I_τ !iXdd$I&B*8yqj`K/umS[!{婸8g ohTtbbndԈK{))-uzD|fm18^^]{'|ܲ:u?[=W3u]Ń{"Q]u1(I F,+IE&(Bt:L &!}۶}gg( !D3xhV/۶H$d:5$I,q_EQ g(D/@m'MSq' `4MF&A+mWImOrٿo㹧e?< 09x/WJH\{Rj{h^Dr"-5Zt[=zaODJJjDb.2`4^pܚZIVP-"ǐ(dY.8fF"+h$ @'UUe$j dn7a1il(F})/NO0Mu1U0l/6*m4"4Lmll$b}6ϚVi1Q4bD$2P6ضDZ(( 0Di۶84M fЪԾJ"H;rPz7'9{ߚؾaOdv`سcשZt^}f IDAT^~)S#[4Rc[oΝ,FQo{#?߄ƬǨ^ +Q#4̲,AP.u&&" eqE:zq*_=Ô b(N祡3mPCzD2nsuts@-l" EQ՚T\+GZ̰yym}i;==-RQoq.,,0&hPɔG(l{K0Zَ \AQFTÞx˚VT:3/FTIeb{rK?X7YHII썼~> v `4-Q<zUҀ}m3eȭ6I!: Hg V&#pLx&Mq0BZ <|xL2fl6qSEi6_} (LQV3 2dԁy7#}h~*v}?c nU[3MB9߸qcffAL9?b" ðP(GcN4]H$|8NEݣ ]6HE@J>=)챬cǪJ8hRQ(Y]4//}~)itEɶRRRsl-JDx92tK'&,E* &9}GQvx6E (:ǀHuy"n K/`"B:v# |]e+g4MӲ  X\\<P(fvR4YUUt_2 B@RXn>vKۭT*ab8;;4Ml@D sUU6}_$-DypJTb|Z#A),{F DJm~`ԩc@Diٗԩcک'r/ߴ.6Ͻ2쉌7 Ǣ_Dz|wsO7Ͻ"JyRHK~ڥ+;OIIILk|ƹab5/ڇp*/D$;#]<@TluE|iq e=Puԣ(QQx0qT6ga"B9D.Q[=*RQ芝F}߷m[ 7i4Oo0$ ]mHoܚOڱF *!m.Çƨ&z᧎|m0;l %%}J_x_8F[c"W<<㳧&\ldhcdɵx$wEQ`^n۶bv&l lm| L0 D0^gcD4M|xzjU#`vmpz"Q1c3&6 /|q(j $g,u" ÐQ)H%Lb.ɏ@ڶ>MA=X*r0x+F sb0,6s * @v•-6udZ31cߟ(U4/52.?H>H.I?Z\hOf=))aWabuvsw@?vNp_A9|( q@Ij56YA'ꝩ/rfۋ\ 'R\bEyzbX(84^by(ϐu>Wu<>qPmGD/3P@L%> ,ZcD45@tU*3|vjSr,SOSrY`]$"F˚W*Jc/][yW6$wRc_`TJj*z/A_뺈 !PKx/'>XT4E>juC&d&Q^M0G)`TK^OFu0PɔJ%Ʀ DSDF Fԣg4Nu\!NOZ.1@l&3-hЀ(Y4qwSeYpׂbs|0DŽH4ȏ3Õ3Þ>*oJΌ5T4/Gj%cZ=djҕIR*}z~oiQmD1"šebSH"2M #%lDYV3XSuqP#FQiRbFӓPl6m<D<7D: DEL1 YUh(u$4MZ9(ƯT*b34ȶmtؑga bS$8`aqvODX;h a(NXj\ر 4VOa$9>짱iQ~~)xF帚.wZDFE9+:~EV ]*o  ɕZk?k%;e°gqڽ]h| KTһvj*"^" ށ8nHOf ]$1y7== i(W)uIô8`-Z4M]?"4D V-ܽ>nt!kG좨X-T4t kҭT[o\B>M@Qqmf<Fa&z2?a 0\~15M$t@{R𱘦 aJfDid@ewEUBeU_ĞD"l&!ED) 6u^?\xlE/:C55_NT]ǗpyB̀|mc,&aVr5=rBH~w">:*\E861V>A+UeSs]/]@1W'Gmvm36JRJ?ԺzBx?.fUnpv A@, t,&)=vq AS(}.hOR{몪€K` )8)Ⱦga'U6O[=qL! <"])Qy0 9_B@zm:55eQ."r{ -)ՊK mDϷO_ FyY/dot aG'̌t0e*vluvI6˗&0J xY}om&H53[tܪyc@V`G734M(`arPHɤC,Z*q0S$ Zi3 cLu܈[Ų,t]r{X\ireMiƪh8'؛(x,(qxj#o#HmƞT$Z vt]i;:BE-nsLmFrM8zY;&rOY%f~ h1FP\0|E bylbk5@ 4{|(joF)VAjE6فۤH( `0 YZWŃ/Aa. )b&.A MR!q= 'UUƞ"p>>n7 --Ue<+w~u,O`Ӿ(w@f]= $ F0;7a.<҅O9*–u3|m{|?{ҳכU9;3@70ˁ94LBLwS%"X wC;eQf}]!*VL0^\uQYQ?ch4ZM:!Jr*Ȭ@ NSiaa8teVTE7D\zݨY^Z+*/yH Q""ء~;"ډ%7$vI.v0@ptZ5Q%_9W=R勘ur'9.1 B$I $=h4zH$.d2`f4U p EQhf8n,5Ma܀߅@¹Hxo0Y(0`xh68Y ?W7;F:Ց!vߓf*yVQյپ`\\?]BhKʹգ7\Ϳ;$vI.]nta,M\k?<Ϊ(B{ ci)VUހC1V>q8Z_%jq˻6(Y) m(.,,8̘NfTEA<4n=ixm`"xTBߺ(1AW{8unބ.` [vY6Cb((l)o>[dSO~q~]}M~6 "-!m&=$;ќ3m5E zӱ5g.WbN&ʵG>7$va.|B/Ϳ,_isI!wb=\ޘ[,gANuv0 =Oߢh3Œ{rUy:m %IQSqʼn*R)A;^ǾQawEQ2 !( Le!"``Px<A (9 A']A?>ОMrEبl6 8-}G}^0!B̯G'㣓@oor5M̯ϯiW5&D:~%4)`NF1_c0]"QD0zylbǂ@hj ӹKm8_w?whV#cUs33Л9Ze/}U P(! OrcEQtZUUpnBc4MKa,S MFQ^e$QALL&>S83 /{{t]8Nb>E0{V`)~`Ƚ 8G0cnј[NRa7Щy}vLaQEazc,wp_+ҭ}v>4@D<˗0J 4)/_$ ԩ(!4T _`\ 2fwC]M3ܖ8(-2 av(ivUbh/b$4 TQP0Cܣr*qEJPN8}`5볷ÃKTu"ͳ,( (DƍZe7/:0DB'KhO -+kW0@o`z^v;xV״+ݚP?\'zk%̯[S09oZpStpy@0;%ͅ@D<\a:WXgi ӹ[Er#N aR ZTej#= ]8bii(,R( 4i`.в,Mh^XX( |`NMM0L$)nEY8^Q"p:OLڇ IDAT8.0 CKq˲ @P˲D²,{|2 BZ%I%ڣG̉W7_U]uRc:BIoBug3Gz_lYNK+f~$ѺU@ot-U#e+gw⊄v,o.us]7dKD%˽ 6 ӿ_r{oFIh ៿_ffz7/0 b14cf"Xd2T JAaĒa4MS r QK% }:a_$lgk:8β,O$P$B(r9 "o<6P(ϐ +I SA'ڹ~z›vh_Z0sP^>|3/ I f~%vϘHh*IOګ3nODdzx]E X}w?B6⛛_߻>_]'bh5lG)~i~L~b92=rtsǮV`%$NCf`!x'Bz4 [(M7p ?<}0b,K͊x@ >V0`\>86GQP( ,{~[w!N )yg} )H)@}$&,]9Hw+(L|t«=UPk ΁ʶu%Uo ۄE 3$S~s|3.,FN*LMg0 sF=0l6 bL&N65MKRv`A)"f0 Bieil5Mž0q}"f,˦iXGʲg0h.>ir[-,_Yk֝GM,q@uvHylZcPdh!DzءP\E$ D܊̍#/7ϲkǮ#qU !|<׻9Ε1>;m>.s}o>RG^o G҅O0J {\;\iatԌ`\Ѿrj4\Ց$)0b1 b1i$ѢL| 8qlEɲ,20,G"G~*Bx( g%IƒPǸ<ǿ EQ(@ 8"+/M 3\ܢ1c(0L KVғ0C$AЄG6E!^yk;TOku /ZkW̛vpC:<6 buOɑFWQĮ#du@ 4~r/qsGiat?o%Tc5Yey;_ zHn˲`)˲MMMQX~v P(':,KeQq.S,3M3Ͳ,S@ M&XLUt:m~Ű&;>>a4M,@@h_Os&|Mt 9`Ԏ|p_ BM"AzvVq\K$F]`/nNyCI_DQD@ 8F]Xkrߨfa6Ǿ,~B;E hTŒ` `i"A@ij$F{PE$PHuF%Ip,@cVyCD',: i'4P`BcWڪ#~sH'\{(v0qm];vy9Ǎ.s;&Pm];”1FؙOxG42tK+ܢug /'zE<Ɩ;@/B:sy"(B=dGbщ4mw?1myq .}SթwV{4.ݔڑ/N$ةPZC%D`|@Cs14RT~dQS)D،r`^%ZNġĈT~T?m D"KKKp8 VT6Y(4ޚYh|^QXKݽyf0ٯ*ꁂ߭+4Q7Qh^B.fW'CQ3==<?|4@ qUv=<-MH@Řu_y%xO)q1s_[OTd17b=̬]B*Zd F9{vcjԈ'jp{is i 鲷~^lvI*xN B<2:P(z^xAޮp$Jz}MU&"?Y̍ipn?T#5,T]W`ɢ3k.|L]6@9R7(oܷCyhxmS9N#uQA|/^Ȑ$YÇGH$bZ &p8 DQbҥK$-А|@"my{Fc{ʯ䍵p:%9MY̍^O5EfgYF m53k5 ȯ>fd띗l z*[Jśt&eAyqI>4xG'P%ZOO8D"Ӓ$ɫD9>/ʧxkH0],O.s}!&}M9B >P pK+ɦlw$~k&k3kN}-_}xv>hHZŹr?WRw7~Y)TzQ8b|E"X,&IED"ctt4W8Z.*8.^ :11-Xyx:5$Muc9r+e*[CWUѭ dX/"*(&:tή) {T1k+K lW)_^=}5X (}oJ/ȳQ.nd17 6NSiPZbn$ GrrV$IpX@ z?]F8qV zb1_z8yA4h9Gn)G6S@f1!Te *3/Z'h86Cl-1vLgZShT F9@#R)1ٷ7~#dw=卵|b6e4XFݵ)>;/pH8raәepH$t:Ia)*Jꗖ&&&╤CCCCCCEvWL#6{ lkj Qʑ58]2ٓ) K_SU?z㿊vc@#hj$vvtǬjXvTI=}(^L91TY̍Q/!~\CW=X"B($i~~> {-(}}}%<I\.W$ׇ_zIm)@w!b|BMDOAGlD6 Bưp ]OC~~Yh>l/VDj|cLSP8#S#%rT0*g\ߢb{Kk=9 =yc-o4}ר*kʺq5 *|ie7PG|h8/V:(85b1ARTQq mq8&9}]cWjC6 T4!*w3,F/_kleؚYh|^Ͽ5ڧ8`* ~rn?G Bxm9fU`t8H4Nף_0=raf0l&Ŏ|CQK@6 @RQ̯Y̍+w^p|©eBWmjcfsѳwȧY@}˗b Y{ o4Pońn?V>'@iJ0|EuJڹ~LQh!(* _Fk|c^wF}p)k|^#]6v@ CEK6`KV>V~6T@Ythʇ@7֛VD*c$d/HEA;|cRgeќw^nU3%@t0J +NzwmrѨ0f4g(:WPt³eW(w@0JckUSnVX*/(~\4JLX+:GW7{N%w@v)PVHd17fhkx2y`(PKr?eM-LydR=sڿ[O4?ĘQ(T؝0d9Vs=/]"'U:Q f7yD| f9wb}<-E`GÅ>Blec&/]o$^[ 1T͔m mN+O_'Z̍])bTLy)*f ҽ򄬤O6lD;>ݖ.yA0E5Us_ko Huϗ3Ԣ^92:f.U誱.՝zzk6^ܚ[POO?DF}{pI^UZDf^BUUPF]Rʓ>U}9r H1GY%Ls_c!fȰއU F_=}5"e;tR(BQK>d<`DMMm?uǬjؒ\EB捖*7{bnJb{#J^k7'L%'?_NsxmS\5U;)غq`㍵ލsv()_%WOiUcNylgi;/>BJDDM JhF;k s/]wOQaA❿"Hl>P]lwO^N )>N]+L#m*䍵 2- -hyT #-X>;|UW#YZRĦuPyz%Kz4F`(Bר*!sJbn[;7&S~OL E|$Nʹ>QbI饳7;. G=pN((^˞ xWxcm_w+j$Ck79,Z@g7`)ai˹v sxv>dfզP F\Ϛ4I![*=Sx4"Pg}b<@I|ON}_v`=AM/MZbCl _(!L}bkCl[Htڭ48\"QM1٦,5\G&>E~z|kf#Kզ+dQO4W(m&ZDKw{K30& bngq)/pŽ IDATd ^ۤF ;”A;빴o}Q.ZBI"mhz~ s0.Rv@ѐzIɿ<_FiX̍ rl]b#[kt1ru(@y8l2t~?{uea`MجYu:L"wEIp8Q% ɢZ[Yty ? iQ 4. C$,Yf@"t-{(==p#dRÙpLyM0NbgRJPp|14ykyz@{sy~{L?lSPY'gk=WnL 74PpkhRDkA`y5۴]" 6kݾyh:s]>u(O#Gk%mU\kRPĦuK*Ssf,3?‚_pUՕ@yzLJ>>'Y&OhNͷvp9>mKX]^},W}"yǘ p.;<ǿs':}x`+1l6=/W(FW6Jn+.ƓFe|G_(.Ձa1oj~x e4!9fL2/r+1~CvՆ q=_WX[-p74i˷C+@ !Ϝձo<&!HW0:4/=T2 ӛBQqa/`JloMk#3,r:fG'V;v.ӱ?kȵѕ d]G<^Jpz-̣9>$~4O;+YttwA od*g!uFm>8`mBWFe) 9in)'P8VlXbGNX+k#"`ZoO, ^N]Y퍛?yO,](9re1\]5$%vCXh@M~ƿ׋^ tY28hQhdi6\l,= ^-_!&"l ilNv \{ʕXb'zsmz3B{Ե!'% ܳOrqsBѬo9}B5Id*[H&G'- }@?ñf.&̦OgfOF\m-7==2"KKWvoi[@֋4~eY%ve!utOCTNb{\X.X=^X ul|Q\b'd !/cӯKH и$6BHwG~ŠT:k[! /+j;u8{;N5(@cQ1jlb<e"%{]-ƷR,(O#K׾o=~ee༅W5l>EBGȵ~,Il>xk,!ḥџ3y8+Vȃh38<.#u_M`)(f6=]PV-TqpgPTo:>UˌȒ^'X4W+u+,=)$SYox\T=5^حZzxx_SCLP[og`ݢV8Ks}W@CLB#K뮽׼u 5O0\,zE7WMfG~fG F?GG-`V!-#A!Tv|^;xt&CVs)/EX[4$}cׁ}hP>p4. w"zlKWMH%r;huL'lGuKIP҄tDIE阼ky] ?wI1&fhN u#B!z`o ],\(BpzP{w tX2\P~e 36KNTUk! {5g?gEW6".k.A_*`/5,Z ?Wyhh/_:nmOoj>T,ƓVz=p =*R~)_o&lS2/+ok>׈l`~:dU\jq_jH3Oz5jɩZu]re|^q͎y+׫WCpO'UՇx=n=(&񤜞͎(v5<ʿFSԾ#ɫK[W"OF#ޥ) -ʲd^a?[Jlm++%E*J[X5SLe/EùB't;b)ln+^{]ih*+Trky?dfҙ|OhNQ+K&k!T泦Ip5;c=_x\Oɧ7FC B]UQ"MV,&%vA/GݐJ54 ->ve&Rԟ|+:BÑxp#o&RԌw3å343\ E!>h dGfKtu:\Jt=}R.z]{Tf,aQd*?^͢`H}ճ郃] ~{tg37,TF7Ԃ4c墄]ʞT?d2jm `?FQ"5PgZA1BZ4*M3lQ" ;4AԤ9 W}:4# 8r9,1å5ΐr[gv=f8ثseRg(c2RQ ´wdvR9wKIl .CO U \ӓL5АOcxRx.!,+J&K,N9jH'l8hj{v!M`0JNuͦ<rAeV]!fG>9ahjrgK|+{Bo-op;̢"nOhnjn]hwn2O5ݹ,Y;uR4'CMJ:\[}Ef-..[W#Nޗ5O vjiKڻ|`Q5ry%W)jG@5!p^>eHL^QUts"WR.Yy%]}/fzdEW6:_^w(UEEWzn&t6ta :[S荑3Q`ʉgՅ>>$BQ]6ӬZސ:`oռa4W2,R2Z9H#ªy%Gġ.e8O%Z5}l ǯ4 (k|^\13\B9 b:J}-&~_Qb9fێMGssnX2SܯC])7$U!vUr:&G{kFW6{Bs?[Uo =Cb.E^H u)JFLhYpu W:S0Xb?UrTA\7>sOgcs[G}T2>Ų/Xm|j4K3ٱ^{RteS(.f m,ثgg2 ?5 L?A(6n]l2[<0L'tR~)"Le˛B6@cPu5wSD) !TVr:ߜ6 Uuu-\NeQ7~S|?+^b|z4)RQK^Ol0JԳ^W]iTTDW6߉rfKȵ|+jĎP9?C{{BT$G#U}tд'ɫhvm5Bn[*y=+|U*Wh/fr4~ b}v?Q4Uk: -ʎ$.]N\^XUrebBHڻ"Es'\r9.LP+ W)C׳35 %RّMzk#{E5{rT&3xTV(C cbkH;P^\1 @-1C'mtèXbRD1w* PY̽&@>XfnUM^7XIAKZPcQ";`mvDOt&^2Wi6;Dzr%Zg #)| Ui~BO?7eզhpQ;z`/]B3队} /U tq@B<94e2j_oAC?{اPS:o]'T0h Щxm)8˗/\NgaXS,#7Q D?{ƕ͈K Ma¤L MYhMi$Ja ֲtT@D i9m)GE. [0$+F- IŴp2 e7#9D}?X`3of~{_fʕ̧su㳽9qARþ2$ k'cu?JgxHs>]:0*78 TJO7'E \O(9ws?v>y{RL]"&Xlaę9 gs ]@Q"j7O5TYT G{s]kLvU8xNzϯ .\P~$D?> /q rץh+r%yK. @9bd'$ZGё~Eى{ |K5j )/(-r撐?љ<!]Q! ω_[i :4Dpzۻ{=ΨΞ~7?kݿH!ky¿~_Ǝ7z+U3 nktR^!"iFgC ãꢋ3[ڃS\%xřA;'++d]d&ԧҙNȫml5=A ?M=xs=.QQ*Jɐ¤T2=ф$[)[X,*gBmtǍ >yTic+.=Fg< GwzsLE#-m9@$0hҨa+Oj!`_d3=-*8fw5řAqT \Yݘm1*̶cG:sT;Dx J#]@L(KU"gɻw^6*A*rz\-&dsT3x\#UtFoŸH+iLfjt&[X5UQ"S@4;ibTWkbbji&?-~ez~PZ 7z_ ?ue4vu):Y__]5 ڬ&I_ZF) upOcBey )6z(bf0IR2X|۬řAkvcU Gs =hHiv@יF$YBR^3Kf޺&~nt99t@[1<̠B *'($Q6J. K(!$:G9lN h]ۻ{~qnƚ[~hzc'$44uΣ7='$ :0L8x!+$pPtFy$Ge|\WFa1Dgpc^sz4 d:>LSP-Lj3Ζ:8Ou|M DLLZfjEjQTL(!dj84/.J٬HOc3C~Z41zr? ja]u-6z,FS&[*WR6eq>QCr3ΈIբE84FB6WknUJLJb%7N6%1yIS6pHϕ٬THܔ\ SB6I۔JoU Ƈv!WVin|4)#݆O]a}n.IZ54K}8NuXmT|D]o 4R*Ww++Oags3/9!^Sav=hZ0@T5c_F尛aOP6 @-t'B(5!S'YD'ڛQBH8xγ-#oL*|$:H3h@y-OKDk:lqfp{ nu}eí ?<Pvh>2vR rq޺=f{w' DGeT<r9ӣ2=[ش[7I\\rtz=JJzcA6'dsťSs{_v^xZӛ.!5cjobRt҉sHևuM4cGܜZ0hpX tyZ![dž?)݊Z,/PsV3HI&h.NNϯ^{=N7vy렝T-Ӎ!"tg;ńlNw7mVK[+ywK=O&)SC>ywӨxȲ:"_13zF#nC7M5B6w'Io4= T!C7`ߙw/(d#7CFsDl*PV=;4G:c)+Շw}[*W*!尿{\8 H4]kR^_SN-P% .+; FIpdvv FE6rbZ6ScZ{m*dt_H z.4B1->XnE\_m⩤2ΧTiaMd7&H k:oLc.E7Jg.E)LG_tRO(u):DsǝBzcu]mp)Ñ宷1ueqfVJWzcߔz4yQ*Yf(0ITT:}/1jaZl4%$z&e2+:D!w7ފ2T$dsÑP\+R8=V(`QИ#6D4PdhHt8]! U Jעp0 ҙ'F]NY\B#,t^_\- cҾ:S>ww2Z%*ZɱzL0N2|o;vOX2CT4_(J3L+oLr>\^15R#]HotC N?!HgokT:u[sRN 50B \^h6@G}F7XӐt4 NKG;>腱>S;]"^÷c`[D|M &Bl(3glË9sDEeƇ[z[+S<ˑotfgz~MVK |Y Z:m\ϴ^싻wiȮѾTYwBJ= :etGC˰(!$18IiJr9&VMz;r exTT- %B>:}SrIh|ysI`Sz46J/4Ju| !,OBhldjM]blr7Ϥ; Hvwt6X{CEuT=ЕGG:! R|,y;cuJt0r|/(,&O_#衎,M_afA7mfV MQO. Lg$ٕ{;'2#q~+ޗ 5'Ԫ|/w}SmΠaW/Ϻw=܃<Nϳ:F{s^/|$q:ѩ֢TZ}y[X3`laqjpJoWh=JF >2HqShQj u_8hMG^N87c>4dIp^ _}eݟHFFJyiYwݖ3B6UљЪ#?לSbr_N= Ͻkp`83:wM#4fcmT8ӋD- 2M%|3 _YZ_[#+;l }t ;o(}JS>vNLUw7\Ưri(*1[*WRo."dcBʤ*Knz~Ӵyji/T:$7b8r6zQt >wbJ*]Q9!3_P4}cP將!+B1غ;=ziz_vӣ|8_Q~ eQT>Ӎ`Es>-b?4!$_(֔/>w7o cvuw6#kRtB]-0(C2Y-vT:WgUřAnXU\U@[:EEbTs<}[X]IJ }2+Z>;'ۉ&2=ZTؙOV5wbZƯ>[9HSĴuy ,T<3&&V+M.AT(RElH,d6@2PͦgDӊR? y:r}8}(摑*,Nc9\|U}}=TƂ+ e)R۪d{]0{_:ULT=2/i;WEAFrx#9n7ǭx@4Cfo[Vo\˸\m!Xڥ<+G/v?28կM [fbWJq,N)|Цb0-Gً~ed F'W55VfFyN=TX[~pKj}7,`rlz; 2>tn#9L&S`"/]=lH6MTao; xaJb;-;=PZⶕnPxEX4Y); (BH!BP:WY !`W&{ ܢJʆqménl[ĕzVƉDʇ9)vu.RDM0>2aB0zlkrS7(sjlWD6xB493ne~QdT XX#?|j0Bro"DfbJI;e#9L<nkj *+Bu0*;P?K:gd Fߐhߎ! k-WE wK÷ƦWd]#DpBbȇ9eCP㰞6% %.IԺ"D9HCМ&TmwQp,N6sFCsI2N\LTWEosJnmLaz' -ޙe ztDzeq߼|ɫ=Y\~gr;,2 jHn>1ũLE+1VD^):6Ym^9ftXa|ߚ]J}?|s0l~ht`^;+=J9%S\M fp8L!J%0S\Wk3m1(UL1f_?Jux3G"elZbA^ YX7М!VK85ii T4'Na_;AK?Zy0l0$]VJGU|"aQTT@XmPVUp(zT c88VUQDϑVUrhVzqsb,ķS6?([ck'éVJ 貝8f;,6߰1XLo+Cy u !*lFm5P`Ye&-B|d*cQ"RQt}4YnlM^zJ X iO3#`nX2G9".s+G: K4Y^U p5Frxqe~IEҲ[y,|]zbsLߨ:|AǮN\7fB 18Zz B8K#6p ׆cjjXy1@t55u,56iS=j`!qhkkLܿb{(9a!43'Z!I"\,Ҙn+-E[257v>V^hO}GOs+XS̓NUy"_$7  WRVGJ nE6] gb-ms)c!Ol0mxv.&#a0fq 1)O94T"f&S_+=}OQ S A풽=g%xNXG (+wpH?"EM86TFwpbʺFsqkc=g^_8zXDBTfpbYt  DZ/Nސ7[Vo\끃ˢ(hRyAo\U11 N|_r8+\M KJEe.p 1\~--.᪹c8@hGZ4ZՉ{ˎK]F++|]!yF0, ϲ(Ig \^-V(T69,] 5B}G+0.fu[J˪4 a*vHJG/vGbiijl6ȭkMb; U`Cj3WSCM'[, RBHvPdeCIW JW)Д-+ 3 _ mBh Ck!/BlFWP;0*"F/v5m]2ǓIŔd*C뷗g'6ey6Ls?|Y\ɆP*^Gef BJɔ۞tGZ(ppIz:b}W['nRۓ/>f1T 2(|j[n5 Y 5$s9.&@!nG`|kl1p[-;Ug%lk4=|uLea!8/5U[Re* D?Xm9}壑|/̲vơR}ֲD(i3|Ҷn鹌NZ) 3[Gm_9me9%D2 w; xQr8"~qe+B,L;8$&[v0e v) 0W|h c+b6ceSwV1@Up`m䫫FiaTltX(Tt0p;qJ6*Q+sO[L]f\MH9==;.ZȆ ?)BFj-*q8O5DYr`Ws=Me:-e5Nd"&p8US1SCI+`kz^Mm_<| GV:OG`I,S!hFeF5TqyႅE!eG| Е*> c+n.O:!y'BK?0:# Kz;zƝ=JݔG:G:}W[~\8257i>sq~TflzEtv55וVTNgTva" 0J\3̞z݂[3%`Ao[WvfH'S|IiO 5o@,0c]Np LJ{K>E \"6DR2  vG_؋]`*`G`%tn)=y2X4 Stp5jҰdD"~%ë؀6L[kօQ[q&S}[8`Z-Wa,}ok"576:|umMJ\vx"qVCقȯť!#"=&*Ee vv^@w {o$Wsx?8eȵKB({Kx'/aNR5j kD7.%+ yvd< 0TZ,T$_;WS d*s2َ-)<:th>{=ͧ>'Q|Xb"TFįG[b $~d=()>Q 0@"qAL"x;8L*mh !d} $. pj@$lnRES(gq_3q0ܲ#-V5?!1 JK" &iW(J[&H-!qL|Ωn,ͧO>m=gaޖmԉ_uVǦW ͎;j-%BsʎQi#hFOӱS8ĩMRJFHb0C b8'(X/ Qjwd=o-jd.g[I(Bh&v! r &\Ԙ-g?sS<V]zqvXj};6UbT)ajӇ*t:۶N476vzBU/P 'hZzZ ?q&S/~duC TOT f#aa0C b?/p$Ό_WQ(WUG`Dg}CVRSI8}q}0a!z(}pb D R'/4CXXRv|T6٥h X>y'>tNk:,"Z{ΔOOPؿ?}}]=plfv)_zz-6Tlwd?.'ٰ|Op [s;hx6mbꕰ!hT %^t0&NTRn)UhA/n \&IEw^BڳdAɀcZ{57},l'3 z Jg Һff ̸ǮQɐ%V%a)5]˚NTmf '8(vU4MK%8E017*ModK#VO6 *ܾcL(b8Տ(JO-!|{_O#-GbΧoz)"&v{w`i]y$eJCC·(J,ba%*lR`#W:G> Ou_> ^k31||^+amtt <2-:[с0QSvK$[Ni*)%Sߩ4`kYHx46Wq,EӰVZQ_;F-  lF`y9vZFIhQ`GWtH0$SBZYG`ԂO6 ik͍_boTyX_,!ﯗG5?htB蒡 ы* Rz +$S4Zd!ٵZdCUg|[WtT&-,N;éD)gɼy3sK٥t8-Ģq''EB|SF_5=ECvo_Uz\e;XY_qo7bv9jA_y¨kJkƾ.Q,3xD0򍒽L鱣f頙h穽(1#tmi' 'x};;b |-jm8Lw6]Y ح,29D!ZQS{S44.))i ޢ4\6WeRY5 6p$C;5`5̢=gYF=CKQ cOw߽HAtE>ߟN CuoZ|ώ+8։ O6/cВHAn_jǹM=.^(muRzB *ƋY`/q13C <.bQ>DyĕEUR]+{?6`C Tz7VT8 ڨem F!S;栤XSbсȑ&<(nO[8nᝎ{KIv||̑ {aT2 ̗em䥠JeօRýA[M(BU=rGj_s}/8_\&eɐ@>(*}ߕX@^؀-NfPU(ٖV5oq]/.1; F>75Wp4s-Qy:T !_ѠjǴ!uɯťMJ` 6~YmTNؐř$vë((cԞ01Q%az<2-MKַV7 ֳ8ecu&dI:-Fofh77?}_[vE].5"yɄA9vbpZ@l&m$唆gAH(,/k> M;Ԯ">z% (zQ %u=r`^H 3-(&ʇ *i!f6O*A8.s|Z( t SddI4Ik:zˉdÉ=┤;Dl>J}E~]Fkܖ g4\rQ iU"o4ɢ&-D/j0A];׎嵫Hkŗ Ci4,Dp!zV4&vO ?7m[!:6Y?(\2ϐW T(nkd6>gGgX:f-*`Is8:J[TjIXC(ťP%w֬r&ܢsh/iHjH hWeE2n tI79 )$v~qi6_bj)֌! x6橒X٣nv&03sT6vfQN¯w}R͑QUʇrj =,59z3 kD+s8ˉܜ HZM**I/E/ A[55#q&y(quTMɗFљ8dm.D@*gI*,4l7G(*f$om3B-q\jL#z]11a$fV夺*:΢!<8uPNK.NY,>]UVŽn ݀,q'VFof!~q"=%{AQEP0si_LʞڨU(ALyt1Z}Z[FMGMfdȁ+ 4lkBS³4d"iVXs/.E22(O+{,„ 0*)bꢍHAGZm,RP@eUK[zɣ@r5X8$2-=ηz9554g3wPN=| U!51q9ea/hPkePⲿ8AF VAAՂH"*^/LxA%ZbaVЄLYX.;GQxOeXf=Y0*|iU6K & ,ri{ϭ۾X$!fzb9}*ɣ, _w5_؍g֎V@1kCRɶ- z7u\<u2Heo~z,v%JF铗(4Jn8xG#単jc|K֔TQ&*P`S`&H'pS"f(˃ 6<.I[kGpΡ%p}l,YZm@BD\~ẗ(s{v 9ß6} 4mՏNG'JOtH\ _FY^- FAWb]ӪO0m.N$yToqFnXH(:yNڂJ9C=6bZ^u? dTQ&2^Sis8:eֵuJX5ʇrK΅ hn]^0"F|K5z3,<)|E ctKdIk>;J 2-hRL_(jfˀ9s+\`@~Csb8mMÆÑ+dv,RX~ZU2GO3GJ%Qߟ3ɗ0kVyS˃R:#;>xJi^ͩ_eҖea+$r m hwƔTVmyPN -vj$ѕ(*#j"('(7yDy*(rV>/4pE8i|y/i,TQ†@ d<(A9]RLRgO Hfr˽0K+{ÄmL8+f,H/I*3-qX/v8k+=K|k a Q>4%|Źxdȱ=oo᪔ҷbʝFI%ZZvq*sKApXSؠGO|Xrcq~qV`}pkVfU~t:) =+Ug-=CW|*ƕ+Jؙ4ԏNe{hJ228(%a&U ,D0AipЋC,N h+sK'/b:>YG %rK'Ls=6!MfQu᠗TQn=+84\tvqʄm @:b慄Aj۶ 8 o{;X#h:zH? Tw4H,$B=r;T†\QačeYݱ;2Yy C-dYg )jN N IDAT D"fMyn'O?zW@`ÊD;r;̶f5O)/yWP}O aCS\豟Ȑ%ɣAtͅBh 03k٠Ʉ54Fr#@vaq({$l•F9HʩI q/.Ҵ& Ḣ muA9qCYecA{iI6 8ݪȐ|wZ&Dlj=89*I<.g15[L֏N+;iS=.gW(\ō"0fm>l^} `$ω.4ˬ >}?S~[=[E챡Zr΢BiU/ `'m=H!v [!]vPC _KN7 FcTb>e7 8./Wv/M7Sͳ_Z1qu!K<7<.'A`S?:m4`g+,=q{ua4Y_?K:? q\($̃݌rn0 $[WX?6,}O۰Yti4HOKb+&8c'pck nb$’ݸ0e|8RF]ɬBxI0s^Im|eh"M1;S M/ȰwNy1}cHH}`?@8O.Qcy8",>s/uޘp_@M3ɘ6C9f&Fd,df#{S˵JN9-_yi/~bv|J$UaEPj1v/n33(xh N{EFdH5JnLS|D,<>Y5qbjw+wJdv2w zlT)Y-m7H NY-|u36zt*t8\AF)XS mn k]us݋vp_`&|~=k9I?5kšQR=w~7BҞHzH4P;' ϰ]u{|c`jݥ^n%jQV܈;^{j*H)T``jݍS/ΘXlv;o:|Aƪ#3]jѝKIE9 ~-5ZTz{Wo֫zXȈ o'7|兒.*-dQIli6G+8=J-o'?6PK'_7BX|Qjq \LrmVH$7W$5_)vu><۵?|@#0%WK$Iꛊvc?lVvJJb祉-dFQ`Y,rf~|L|j `Ԁ:Qp 9]: 8-]1nW=Q|XI*3!%iZJo*jɠUs4HT#G?.rC(ga/db乚fs~w2P]*k=}:!5&V63f99A'u"gs}Ϧ`ָLlU|/< PlI9-~\ϙ >sEe"?Dd,6%<ӳͿӍF ce:8u^dT"J˵j:0*4G 7ywٕlԹ f||L&#QIC[T9xpڛ\ V{aP߹fpAݹT,C[E6dU:rmr[uFCƃJ$vjy/WvҮ.˴[X;zH0ʹY\{r5$~\qFlegσJ%G/Fuc9/TI{d0H`*IyaCj2qmtk-\V[ɖV9cॸ>P{>L{xė/En}߱/>PY9+?PDx"r }CG}|׺!%["jiWO<|#y(崤d?;uuf@oo_q_QNKYU덅CK4P1/N[U04sS ?~li60FDJD=k9}QjS1*qHHdZbw@|OgZRՇ]]F=.YKg3W+j)=t#gm}w)5g N{7>~vZ^XX6_%~w!OEld5/?KG|FQY7*ݸf$cBf+ '`/:K!oZ./-D!yLS/tw_ j2\Y:8CF1FnԬ<iL>ۮ u"M̂Yԇ©+ A`Gŏ⅓>q{6[mnhDpp◄yRgp[Įo 0bX4H6%po*ْ&1'HʷԿް+ǩ3SH}C|G- ^=ay/58QjEG*.W63"iy8[1g(T󕅵C}$J~]yA7~#)% lVDIMzXo&XcC{Q~yRlH6hoD.krky{|Ϳ\$qY-s.!L0j'vNd{ci;h~:KwPϪ=dEz}PJ쾤bsN\AFUimQ;N2a*ai%P8~Eؤҍ^rة1Pm 1IO4'VͿ<1[~cѓ`Ϝ{ŇJL~ү'|ȅ;qw)6X=k6Yq ]7Ժ"TtT_1jҌ>⬬!%V;O$IRFY/QKԺId(1٣r/^H˵@85X(8MYC/^%KGF'J[D]IOsZoPg]{88A-d_:+|^F}V7jw=a ^f]ȬwW aW󕅵C}+㡭pp"4cA>:/H+=Ή>MK<NЧ*k]Po'.7ǡvp}'5=!8T%΢b߽Pr$lY-C]pT7'.=4 K0(H{r!,.ũZm6VrjBeI(7hjŨ xmU#isY?Zh%D^X;6%t !$X/+e.>z2/N^ K߷Pb66pCXeVyBɖw3>P)b~4[˱HT-X_+f/21V܈QּNV 59%x'Hrxҁ \Uo4 :BM2 Kӽt;d?zR"Q0DgYj{>l޷/2fzmqz*7ǭŽ0eI%n.Lif7"JꍦVGjxz2t\/ǭ^נ9nwj./6BE+W J`囮-D`F ibL*kVS+ij"|θlI%(LwxV^3BBS'^}ϭ\ik1C9=Vz35/~su`F>|ˠќƳ^[t`lM͂*omR{#gM*^q}q45_t|;sa:6~#<6YUڲ1@$ F9xou1k77v |?B؅]xWlna>l=M2f:d+kE߹=+Wʷ H*D⃷o 6ۙZ3f1듩GF3[z/VMkY6BS/4pk_'ꟊW{䥵]jS"*0ڲmu*@TF/W{>f%BS+fڜ_YeūYۥb.덦o>=yml|_7Zߟ>aB~]( EV)oZO,Je(q̶:Gܗ<ƱF j{7?yw*-P Fr굯G:cM}ѱ<,k>f^831ӎ[*) r%+W~ %PME7_ F\i03UCTc0j)MUfԄVCWѵes"D0zAijBSnc`ң̅F'm S]1~k{Ѥ2q♸f(pOz6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH H`H Normal CJOJQJ^J_HmH sH tH @@@  Heading 1$ @&>*>@>  Heading 2$$@&a$>*>@>  Heading 3$$@&a$>*DA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 2B@2 Body Text>*4@4 eHeader  !4 @4 eFooter  !.)@!. e Page NumberPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] 9E . 5%09@qL9M'59<HKNG.uTm!&m,2"2V2W22K33g44w55;@EcL9M()*+,-./01234678:;=>?@ABCDEFGIJLM!t  ,b$- ]5O4޿Dbe@ 0(  B S  ?(    \{p{pXXA&  Horizontal_RGB_600C"`? ,j*$q/*q/*q/*$r/_. 'Z?:Ee4 '`?:E9*urn:schemas-microsoft-com:office:smarttagsplace .eDeDgDgDhDhDjDkDmDnDpDqD7E:E? n C =[= :<PRkm>@T?A^:Rjwkm*rtj """#!##*'0'..1111334 5R7Y77 8 88x9::X===>>>@UAC CeDeDgDgDhDhDjDkDmDnDpDqD7E:E33333333333333333333333333333333333333333333333333333333333=.Mx/`NT$:"8")!*"*V*W*****++J+K+++++++.,/,g,h,,,,,--M-N------dDeDeDgDgDhDhDjDkDmDnDpDqDtDE E$E7E:EdD:Ebb7dh ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(bb7          e8< H^3JUR`!)5CKGyPNeDgD@9EH@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial?= *Cx Courier New;WingdingsACambria Math"1(hK׆+5 0:"|5 0:"|!4dCDCD 2QHP)?^3J2!xx1Guide to Medical Fitness Standards for ApplicantsEGAT/EDMatt Oh+'0 (4 T ` lx4Guide to Medical Fitness Standards for ApplicantsEGAT/EDNormalMatt6Microsoft Office Word@J6@@,5 0:՜.+,0 hp  USAID|"CD 2Guide to Medical Fitness Standards for Applicants Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./012356789:;=>?@ABCHRoot Entry F!ԇJData <1Table 'WordDocument=SummaryInformation(4DocumentSummaryInformation8<CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q